In fact, it was demonstrated that breast cancer patients receiving a supplement of HT (15 mg/day) in combination with epirubicin and cyclophosphamide, followed by taxanes, showed significantly lower levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) in plasma versus control group, what could evolve less likelihood of cell proliferation, apoptosis, and metastasis [147]. This evidence concerns the gene TIMP1 and breast cancer.